Pfizer’s Strong Q4 Performance and Strategic Initiatives Justify Buy Recommendation

Olivier Nicolai, an analyst from Goldman Sachs, maintained the Buy rating on Pfizer (PFE – Research Report). The associated price target is $33.00.

Olivier Nicolai’s rating is based on Pfizer’s solid financial performance in the fourth quarter of 2024, where the company reported revenues slightly above expectations and a significant beat in adjusted EPS due to reduced operating expenses. The success in their COVID-19 franchise, with products like Comirnaty and Paxlovid performing better than anticipated, further supports this positive outlook.
Nicolai also considers Pfizer’s reaffirmed guidance for fiscal year 2025, which aligns closely with consensus estimates, indicating stable future prospects. Additionally, ongoing cost realignment initiatives and strategic decisions, such as the partial sale of their stake in HLN, suggest effective capital management. The company’s commitment to advancing its pipeline, including upcoming studies for new vaccine candidates, adds a layer of growth potential, justifying the Buy recommendation.

In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $33.00 price target.